Stoky
Back to explore
N
NoahListening
A
AshListening
0:00 / 0:00I. Business Operations and Strategic Developments
RVTY logo

Revvity Revenue Climbs 7% to $711 Million Driven by Strategic Software Acquisitions

RVTY10-QFiling Date: 5/12/2026
Revvity, Inc.
Description

What this story covers

Revvity, Inc. reported 7% revenue growth to $711.1 million, fueled by its Life Sciences and Diagnostics segments. Despite tariff pressures and restructuring costs, the company strengthened its portfolio through the ACD/Labs acquisition and maintained a robust $860.3 million cash position.

Story snapshot

CompanyRevvity, Inc.
TickerRVTY
VariantStandard detailed
Duration12:23
Filing type10-Q
PeriodQ3 2026
IndustryHealthcare & Pharmaceuticals
Accession0000031791-26-000019
Sources1

Full Story Script

Content not available for this story.

Primary Sources

sec_filing10-QView on SEC.gov →

Ask Noah

Question the story, source filings, and key financial signals.

Sign in to chat with Noah

Ask questions about revenue, margins, risk factors, filings and more. Noah uses retrieval-augmented analysis over raw financial disclosures.

Sign in